UniQure stock is up after FDA lifts clinical hold on experimental gene therapy
Shares of UniQure gained 9.1% in trading on Monday after the company
Portions of UniQure acquired 9.1% in exchanging on Monday after the organization said the Food and Drug Administration had lifted a clinical hang on the hemophilia B program for its trial quality treatment. UniQure said it currently hopes to share top-line information from the clinical preliminary at some point this quarter.
The controller had executed the hold in December after a patient in the preliminary was determined to have hepatocellular carcinoma, however later investigation of the individual tracked down that the patient may have been inclined to this kind of carcinoma. All members in the preliminary will keep on accepting stomach ultrasounds for in any event a half year. "We actually see the authority freedom from the office as a significant de-gambling occasion for QURE shares," Raymond James investigator Danielle Brill wrote in a financial backer note on Monday. UniQure's stock is down 3.2% for the year, while the more extensive S&P 500 is up 11.3%.